Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415044 · ClinicalTrials.gov registry record · Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,431
- Enrollment target
NCT07415044 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,431 participants.
The verdict
NCT07415044, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,431 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.
Interventions
- DRUG Placebo
- DRUG LY4268989
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,431 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2031-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07415044
The ClinicalTrials.gov registry entry for NCT07415044 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,431 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07415044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07415044 about?
NCT07415044 is a clinical study titled "LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis". The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding...
What is the current status of trial NCT07415044?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,431 participants. The study started on 2026-03-26. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07415044?
The interventions under investigation include: Placebo (DRUG), LY4268989 (DRUG).
Who is sponsoring clinical trial NCT07415044?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.